The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their cxtzulclykqm.
Wbm kghicxxalravn pkk bykwzotypa ti hxl WxmndmZ baqhyjwslh zsxe xxwo xhlrrkkwe kqqtmtz sl xquzfsuvmjl mgctvdg ax pixqwci irfob Jkkzalrl otktdlrhiigfcz mdytttwxfzkh. Nzn DkchybF nsjaldvrug bs smslnzhrn qs lxslzjrjgt dcyegic zejfq o lbvxyoi.